OmniAb (OABI) Income from Continuing Operations (2021 - 2026)
OmniAb (OABI) reported Income from Continuing Operations of 7707000.0 for Q1 2026, up 57.65% year-over-year from 4888558.18 in Q1 2025, and up 45.64% quarter-over-quarter from 14179000.0 in Q4 2025.
OmniAb (OABI) Income from Continuing Operations (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Income from Continuing Operations data on file, last reported at 7707000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 7707000.0, up 57.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 54286000.0 (up 11.4% YoY), and the FY2025 annual result was 64779000.0, down 4.43% from the prior year.
- Income from Continuing Operations grew to 7707000.0 in Q1 2026 per OABI's latest filing, from 14179000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6820000.0 in Q4 2022 and troughed at 18961000.0 in Q1 2024.
- A 5-year average of 12204235.29 and a median of 14053000.0 in 2023 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 119.25% in 2022 and fell as far as 470197.48% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 6820000.0 in 2022, then plunged by 306.06% to 14053000.0 in 2023, then rose by 7.01% to 13068000.0 in 2024, then decreased by 8.5% to 14179000.0 in 2025, then surged by 45.64% to 7707000.0 in 2026.
- Business Quant data shows OABI's Income from Continuing Operations at 7707000.0 in Q1 2026, 14179000.0 in Q4 2025, and 16525000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | OmniAb | 293.04 Mn | 250.07 Mn | 14.41 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.43 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |